| Bioactivity | Elexacaftor-d3 (VX-445-d3) is the deuterium labeled Elexacaftor (HY-111772)[1]. |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。Elexacaftor (VX-445) 是一种下一代囊性纤维化跨膜电导调节 (CFTR) 校正剂，旨在恢复 Phe508del CFTR 蛋白的功能。Elexacaftor 有治疗囊性纤维化的潜力。VX-445-Tezacaftor-VX-770 在双重组合时，显著改善了 Phe508del CFTR 蛋白加工、转运和氯化物转运[2]。 |
| Name | Elexacaftor-d3 |
| Formula | C26H31D3F3N7O4S |
| Molar Mass | 600.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620. |